Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves’ Disease
Open Access
- 1 August 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e368-e374
Abstract
Background: Although antithyroid drugs (ATDs) are widely used as the first-line therapy for Graves’ disease, relapse after treatment discontinuation remains common. While a prolonged low-dose ATD therapy has been associated with improved remission rates, the impact of the minimal maintenance dose before discontinuation on relapse risk remains unclear. Method: We conducted a retrospective cohort study using electronic medical records from a thyroid specialty hospital in Japan. Patients newly diagnosed with Graves’ disease between 2008 and 2024 who had discontinued methimazole (MMI) after receiving a minimal maintenance dose (≤2.5 mg/day) were included. Patients were categorized into 4 groups based on their final maintenance dose before discontinuation: 2.5 mg/day, >1.25 to ≤2.5 mg/day, 1.25 mg/day, and <1.25 mg/day. We evaluated the association between the minimal MMI dose before discontinuation and the 1-year risk of relapse using multivariable regression and propensity score–matched analyses. Results: Among 4352 eligible patients, multivariable regression showed that, compared with the 2.5 mg/day group, the 1.25 mg/day group had a significantly lower risk of relapse within 1 year [risk ratio (RR) 0.46, 95% confidence interval (CI) 0.28-0.75], and the <1.25 mg/day group had the lowest risk (RR: 0.18, 95% CI: 0.05-0.73). The propensity score-matched analysis, consistent with the multivariable regression, showed that the 1.25 mg/day group had a lower risk of relapse compared with the 2.5 mg/day group (RR: 0.44, 95% CI: 0.23-0.85; 172 matched pairs). Conclusion: Lower minimum maintenance doses of MMI before discontinuation, particularly doses <2.5 mg/day, may be associated with a reduced risk of relapse in patients with Graves’ disease. Clinicians should recognize the clinical relevance of the minimum maintenance dose in the treatment of Graves’ disease.Keywords
This publication has 27 references indexed in Scilit:
- Antithyroid drug regimen for treating Graves' hyperthyroidismCochrane Database of Systematic Reviews, 2010
- The incidence of autoimmune thyroid disease: a systematic review of the literatureClinical Endocrinology, 2008
- TSH Receptor Antibody Measurements and Prediction of Remission in Graves' Disease Patients Treated with Minimum Maintenance Doses of Antithyroid DrugsEndocrine Journal, 2006
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004
- Transient Hyperthyroidism after Withdrawal of Antithyroid Drugs in Patients with Graves' DiseaseEndocrine Journal, 2004
- Practical Treatment with Minimum Maintenance Dose of Anti-Thyroid Drugs for Prediction of Remission in Graves' Disease.Endocrine Journal, 2003
- Reduction of the Risk of Relapse After Withdrawal of Medical Therapy for Graves' DiseaseThyroid®, 2002
- Does smoking increase relapse rates in Graves’ disease?Journal of Endocrinological Investigation, 2002
- Bias and causal associations in observational researchThe Lancet, 2002
- Age and Gender Predict the Outcome of Treatment for Graves’ Hyperthyroidism*The Journal of Clinical Endocrinology & Metabolism, 2000